HARMONIE Trial Reimagines Commercial Clinical Trial Design with Nirsevimab
Key Insights
The HARMONIE trial investigated the impact of nirsevimab on hospitalizations related to respiratory syncytial virus (search) (RSV) in infants.
Conducted across France, Germany, and the UK, the trial adopted a pragmatic approach to assess nirsevimab's effectiveness.
Professor Saul Faust will present the trial's innovative design and execution at an upcoming PCT Grand Rounds session.
Professor Saul Faust of the University of Southampton is set to present "The HARMONIE Trial: Reimagining How to Design and Deliver Contract Commercial Clinical Trials" at the PCT Grand Rounds on September 13, 2024. The HARMONIE trial, a pragmatic study conducted in France, Germany, and the United Kingdom, examined the effect of nirsevimab on hospitalizations for respiratory syncytial virus (search) (RSV)-associated lower respiratory tract infection in healthy infants.
Faust, a professor of pediatric immunology and infectious diseases, leads the National Institute for Health Research (NIHR) Southampton Clinical Research Facility and serves as the clinical director of the Wessex Local Clinical Research Network. His presentation will delve into the innovative strategies employed in the HARMONIE trial to optimize the design and execution of commercial clinical trials.
The HARMONIE trial's pragmatic design allowed for real-world assessment of nirsevimab's effectiveness in preventing RSV-related hospitalizations, offering valuable insights for future clinical trial methodologies.